pharma news today glp-1 obesity drugs Upcoming wave of hormone-based therapies set to change field of diabetes, care Federal regulators on Wednesday approved
Description
doi:10.1155/2015/651757 191
We cross-checked the primary patent data and/or expiry dates identified with patents listed in the U.S
Novo Nordisk also agreed to spend up to $1.1 billion last year to acquire Inversago Pharma, gaining an experimental oral drug called monlunabant thats designed to block a cannabinoid receptor important in regulating appetite
Of these, GLP-1 RAs are generally preferred because of their demonstrated cardiovascular benefits and potential for improved renal outcomes [2]
Green Tea Green tea offers more than hydration
